Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sigvotatug Vedotin is an antibody-drug conjugate (ADC) designed to selectively target integrin αvβ6-positive tumor cells through an engineered antibody with high specificity. Sigvotatug Vedotin employs a protease-cleavable linker that delivers the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor, directly into tumor cells. Upon internalization, MMAE disrupts microtubule organization, inhibits proper cell division, and ultimately results in tumor cell death, providing a targeted strategy in oncology research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $262 | In Stock | |
5 mg | $993 | In Stock | |
10 mg | $1,570 | In Stock | |
25 mg | $2,330 | In Stock | |
50 mg | $3,130 | In Stock |
Description | Sigvotatug Vedotin is an antibody-drug conjugate (ADC) designed to selectively target integrin αvβ6-positive tumor cells through an engineered antibody with high specificity. Sigvotatug Vedotin employs a protease-cleavable linker that delivers the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor, directly into tumor cells. Upon internalization, MMAE disrupts microtubule organization, inhibits proper cell division, and ultimately results in tumor cell death, providing a targeted strategy in oncology research. |
Synonyms | SGN-B6A antibody |
Cas No. | 2764774-90-3 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.